title: Effect of different baculovirus inactivation procedures on the integrity and immunogenicity of porcine parvovirus-like particles.
abstract: We have demonstrated earlier the usefulness of recombinant porcine parvovirus (PPV) virus-like particles (VLPs) as an efficient recombinant vaccine for PPV. Here, we have demonstrated that preparations of PPV VLPs could be contaminated by recombinant baculoviruses. Since these baculoviruses can be a problem for the registration and safety requirements of the recombinant vaccine, we have tested different baculovirus inactivation strategies, studying simultaneously the integrity and immunogenicity of the VLPs. These methods were pasteurization, treatment with detergents and alkylation with binary ethylenimine (BEI). The structural and functional integrity of the PPV VLPs after the inactivation treatments were analyzed by electron microscopy, hemagglutination, double antibody sandwich (DAS)-ELISA and immunogenicity studies. Binary ethylenimine and Triton X-100 inactivated particles maintained all the original structural and antigenic properties. In addition, PPV VLPs were subjected to size-exclusion chromatography to analyze the presence of VP2 monomers or any other contaminant. The resulting highly purified material was used as the standard of reference to quantify PPV VLPs in order to determine the dose of vaccine by DAS-ELISA. After immunization experiments in guinea pigs, the antibody titers obtained with all the inactivation procedures were very similar. Triton X-100 treatment was selected for further testing in animals because of the speed, simplicity and safety of the overall procedure.
authors: Inmunología y Genetica Apl. S.A. (INGENASA), Hnos. García Noblejas 41, 4 degrees, 28037, Madrid, Spain.
authors: P
authors: P
authors: Rueda
authors: J
authors: J
authors: Fominaya
authors: J P
authors: JP
authors: Langeveld
authors: C
authors: C
authors: Bruschke
authors: C
authors: C
authors: Vela
authors: J I
authors: JI
authors: Casal
mesh_terms: D000818:Animals; D000998:Antiviral Agents; D001388:Aziridines; D016367:Baculoviridae / Q000235:genetics* / Q000276:immunology* / Q000302:isolation & purification; D001483:Base Sequence; D002460:Cell Line; D002850:Chromatography, Gel; D017931:DNA Primers / Q000235:genetics; D003902:Detergents; D004797:Enzyme-Linked Immunosorbent Assay; D006168:Guinea Pigs; D006358:Hot Temperature; D008854:Microscopy, Electron; D010322:Parvoviridae Infections / Q000517:prevention & control / Q000662:veterinary; D017992:Parvovirus / Q000235:genetics* / Q000276:immunology* / Q000302:isolation & purification; D018411:Spodoptera; D013552:Swine; D013553:Swine Diseases / Q000517:prevention & control; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification
chemical_list: D000998:Antiviral Agents; D001388:Aziridines; D017931:DNA Primers; D003902:Detergents; D014614:Vaccines, Synthetic; D014765:Viral Vaccines; C033132:aziridine